… in efficient drug delivery, eg lipopeptide NPs are among the most potent NPs for the transfer
of selective siRNA delivery in non-human primates and rodents. siRNA therapeutic is used …

… nanoparticle (RBP131) and a state-of-the-art lyophilization technology were developed in
this study, enabling to deliver siRNA … complicated safety evaluations in mice and rats. First, a …

… The chemical structure of polymers as well as the selection of … a formulation can influence
nanoparticle potency, stability and … nanoparticle dose threshold has been discovered in mice: …

… class of lipopeptides (LP). In particular, we investigated the mechanism of binding of siRNA
with … 16 in HeLa cells, rodents, and nonhuman primates, characterized by different functional …

… /BlNJ mice. We assessed whether functional delivery results in murine, non-human primate
… To date, US Food and Drug Administration (FDA)-approved siRNA drugs use carbohydrate …

… lipopeptide nanoparticles (LPNs) showed an ED 50 of 0.002 mg siRNA/kg in a mouse FVII
… LNPs and in the animal model (mouse, rat or non-human primates) being used, resulting in …

… In this section, we summarize the non-viral siRNA delivery systems that have been applied
for … delivery systems, such as lipid and lipid derived nanoparticles (LNPs) and ligand-siRNA …

… building blocks for the assembly of cationic lipopeptides as carriers for antitumoral siRNA
(111). … It effectively delivered mRNA to the lungs of mice upon intratracheal application. …

… Another study showed that incorporating mannose PEG into LNPs led to increased delivery
efficiency of siRNA to lungs in mouse model with pulmonary fibrosis after intratracheal …

… of lipopeptides (LP). In particular, we investigated the mechanism of binding of siRNA with
… (16) in HeLa cells, rodents, and nonhuman primates, characterized by different functional …